Find D3S-001 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Pfw9ylb86h, Chembl5314913, Schembl24780932, 2706637-43-4, Ex-a8485, Hy-160023
Molecular Formula
C32H35F6N7O3
Molecular Weight
679.7  g/mol
InChI Key
JOLORSRKBHXPFT-PNGHJTAWSA-N
FDA UNII
PFW9YLB86H

D3S-001
KRAS G12C Inhibitor D3S-001 is an orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor D3S-001 selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in susceptible tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.
1 2D Structure

D3S-001

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
2.1.2 InChI
InChI=1S/C32H35F6N7O3/c1-17-10-22(40)27(35)25(26(17)32(36,37)38)24-11-23-21(15-47-24)28(43-8-9-45(29(46)18(2)33)20(14-43)4-6-39)42-30(41-23)48-16-31-5-3-7-44(31)13-19(34)12-31/h10,19-20,24H,2-5,7-9,11-16,40H2,1H3/t19-,20+,24+,31+/m1/s1
2.1.3 InChI Key
JOLORSRKBHXPFT-PNGHJTAWSA-N
2.2 Other Identifiers
2.2.1 UNII
PFW9YLB86H
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Pfw9ylb86h

2. Chembl5314913

3. Schembl24780932

4. 2706637-43-4

5. Ex-a8485

6. Hy-160023

7. 2-((s)-4-((s)-7-(3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl)-2-(((2r,7as)-2-fluorotetrahydro-1h-pyrrolizin-7a(5h)-yl)methoxy)-7,8-dihydro-5h-pyrano[4,3-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

8. 2-piperazineacetonitrile, 4-(7-(3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl)-2-(((2r,7as)-2-fluorotetrahydro-1h-pyrrolizin-7a(5h)-yl)methoxy)-7,8-dihydro-5h-pyrano(4,3-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-

9. 2-piperazineacetonitrile, 4-[(7s)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-[[(2r,7as)-2-fluorotetrahydro-1h-pyrrolizin-7a(5h)-yl]methoxy]-7,8-dihydro-5h-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-

10. 2914919-85-8

2.4 Create Date
2023-03-21
3 Chemical and Physical Properties
Molecular Weight 679.7 g/mol
Molecular Formula C32H35F6N7O3
XLogP33.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count15
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area121
Heavy Atom Count48
Formal Charge0
Complexity1250
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2706637-43-4 / D3S-001 API manufacturers, exporters & distributors?

D3S-001 manufacturers, exporters & distributors 1

35

PharmaCompass offers a list of D3S-001 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right D3S-001 manufacturer or D3S-001 supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred D3S-001 manufacturer or D3S-001 supplier.

PharmaCompass also assists you with knowing the D3S-001 API Price utilized in the formulation of products. D3S-001 API Price is not always fixed or binding as the D3S-001 Price is obtained through a variety of data sources. The D3S-001 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

D3S-001

Synonyms

Pfw9ylb86h, Chembl5314913, Schembl24780932, 2706637-43-4, Ex-a8485, Hy-160023

Cas Number

2706637-43-4

Unique Ingredient Identifier (UNII)

PFW9YLB86H

About D3S-001

KRAS G12C Inhibitor D3S-001 is an orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor D3S-001 selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in susceptible tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.

D3S-001 Manufacturers

A D3S-001 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of D3S-001, including repackagers and relabelers. The FDA regulates D3S-001 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. D3S-001 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

D3S-001 Suppliers

A D3S-001 supplier is an individual or a company that provides D3S-001 active pharmaceutical ingredient (API) or D3S-001 finished formulations upon request. The D3S-001 suppliers may include D3S-001 API manufacturers, exporters, distributors and traders.

D3S-001 GMP

D3S-001 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of D3S-001 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right D3S-001 GMP manufacturer or D3S-001 GMP API supplier for your needs.

D3S-001 CoA

A D3S-001 CoA (Certificate of Analysis) is a formal document that attests to D3S-001's compliance with D3S-001 specifications and serves as a tool for batch-level quality control.

D3S-001 CoA mostly includes findings from lab analyses of a specific batch. For each D3S-001 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

D3S-001 may be tested according to a variety of international standards, such as European Pharmacopoeia (D3S-001 EP), D3S-001 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (D3S-001 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty